{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Hsiao_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "The Flublok Quadrivalent influenza vaccine (RIV4, Sanofi) is manufactured without chicken eggs, resulting in a recombinant hemagglutinin protein that is genetically identical to that in the selected strain.",
      "reason": "does not support claim",
      "original_explanation": "This quote supports the claim by specifying that Flublok contains recombinant hemagglutinin protein, which is relevant to the claim about HA antigen content, though it does not directly mention the 3x amount or immunogenicity."
    },
    {
      "id": "comp_2",
      "quote": "Several studies have shown benefit for the recombinant vaccine and other high dose influenza vaccines as compared with standard dose vaccines in adults who are 65 years of age or older, findings that have been attributed to an improved immune response.",
      "reason": "does not support claim",
      "original_explanation": "This quote supports the claim by linking the higher dose (which includes higher HA content) of recombinant vaccines to improved immune response (greater immunogenicity) compared to standard dose vaccines."
    }
  ],
  "model_used": "gpt-4.1"
}